Comparative Pharmacology
Head-to-head clinical analysis: ALOGLIPTIN versus ONGLYZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOGLIPTIN versus ONGLYZA.
ALOGLIPTIN vs ONGLYZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
25 mg orally once daily
2.5 mg or 5 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Clinical Note
moderateAlogliptin + Gatifloxacin
"Alogliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateAlogliptin + Rosoxacin
"Alogliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateAlogliptin + Levofloxacin
"Alogliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateAlogliptin + Trovafloxacin
"Alogliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Category C
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor